FDA

News

Merck's Welireg becomes first drug for rare VHL tumours in U...

Merck & Co has extended its range of cancer medicines in the US after claiming FDA approval for Welireg – a drug it acquired as part of its $2.2 billion takeover of Peloton Therapeutics

News

Ipsen hit by new palaver for rare disease drug palovarotene

Just as Ipsen's $1 billion bet on rare bone disease drug palovarotene seemed to be nearing the finish line, it has fallen at the final hurdle.

News

Vaccine vial dose flu shot drug needle syringe,medical concept vaccination hypodermic injection treatment disease care hospital prevention immunization illness disease baby child.blue background

FDA authorises COVID-19 booster jabs for at-risk people

The FDA has cleared the use of third dose of either the Pfizer/BioNTech or Moderna COVID-19 vaccines for people with weakened immune systems, but stopped short of recommending a broader boo

News

Axsome faces delay for depression drug, hitting shares hard

The FDA was supposed to be delivering its verdict on Axsome Therapeutics' depression therapy AXS-05 in less than a fortnight – but instead has delivered the company a letter outlining defic

News

Red blood cells moving in blood vessels with depth of field.

FDA rejects FibroGen/AZ's roxadustat, asking for new trial

The FDA has demanded another clinical trial of FibroGen and AstraZeneca's roxadustat for anaemia caused by chronic kidney disease (CKD) before it will consider approval, setting up a length

News

Sanofi extends its Pompe range with first Nexviazyme OK

Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder.

Merck's Welireg becomes first drug for rare VHL tumours in U...

Ipsen hit by new palaver for rare disease drug palovarotene

FDA authorises COVID-19 booster jabs for at-risk people

Axsome faces delay for depression drug, hitting shares hard

FDA rejects FibroGen/AZ's roxadustat, asking for new trial

Sanofi extends its Pompe range with first Nexviazyme OK

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

FDA

Editor's Picks